Editorial
 CIPLA’S 'PRICE CUT'   
 Wednesday, May 09, 2012 
 Cipla, one of India’s leading pharmaceutical companies, announced a price cut of its drug, sorafenib, used for the treatment of liver and kidney cancers last week. 
  Past Editorial...  
TODAY'S NEWS
18:00  [IST]Menarini to market PE drug Priligy in EU, Asia, Africa, Latin America & Middle East
17:45  [IST]India and China to be a popular outsourcing destinations of choice for CMOs: GBI Research report
17:30  [IST]LSDSS creates awareness on MPS, a rare genetic disorder through a seminar in Delhi
17:00  [IST]AG Mednet launches new technology to expedite clinical trial
16:30  [IST]Aventis Pharma Limited renamed ‘Sanofi India Limited’
16:00  [IST]Superbug spreads from big city hospitals to regional health centres
more news >>
TOP NEWS
08:00  [IST]Tough job for GoM as stakeholders sticking to divergent views on price control formula
08:00  [IST]UK based Cranfield University offering MSc in healthcare through ICRI
08:00  [IST]Koch Institute for Integrative Cancer Research in talks with Biocon for collaboration
08:00  [IST]Industry wants govt to adopt evidence based balanced pricing policy
08:00  [IST]Study on spinal cord injury victims confirms bone marrow stem cells more in men than women
08:00  [IST]Financial challenges, novel drug devpt pressures to hamper India’s R&D growth: Expert
more news >>
YESTERDAY'S NEWS
18:00  [IST]Synthetic Biologics appoints Carol Reed, Sr VP of clinical & regulatory affairs
17:35  [IST]Siemens, Bayer Zydus Pharma begin STAR programme in New Delhi
17:20  [IST]Lilavati introduces bio-prosthetic heart valve, 'Trifecta Valve' with 20-year life span
17:00  [IST]S1 Biopharma expands focus to include male sexual health
16:45  [IST]CTMR, TASUDMA to hold interactive meet on 'medicinal plants' on May 16 in Chennai
16:30  [IST]Parabolic Drugs' net sales surges by 49% to Rs.919 cr in FY'12
more news >>
INTERVIEW  
Japan presents significant opportunities for doing business
68012+Greg_Kerwin.jpgGreg Kerwin, Pharma Portfolio Director for UBM Live in an e-mail interview with AD Pradeep Kumar talks about the pharma industry in Japan and the future of CphI Japan events
Past Interviews...
 
  What's New?  
 
Opinion Poll
 
 
Should the D&C Act be further amended to protect bona fide drug manufacturers from being harassed by drug authorities under section 36AC of the Spurious Drugs Act?
  
 
 
 

   
 
 
  Corporate
Pharma Stocks
Executive Diary
Pharma People
Product Launches
  Special Features
Features
Business of Pharma Marketing
  Chronicle Pharmabiz Specials
Forthcoming
  Past
 
  Forthcoming Events
International
  Domestic
 
TENDERS & PROJECTS
Tenders & Enquiries
Pharma Projects
CORPORATE
Company Profile
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs
US FDA: New Approvals
US FDA: REFUSAL
EXPORT & IMPORT
Drug Export Procedures
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India
 
 
 
 
 
 
 
Copyright © 2010 Saffron Media Pvt. Ltd |